BTIG Upgrades Insulet to Buy, Announces $320 Price Target
BTIG analyst Sean Lavin upgrades Insulet (NASDAQ:PODD) from Neutral to Buy and announces $320 price target.
Oppenheimer Upgrades Insulet to Outperform, Lowers Price Target to $275
Oppenheimer analyst Steven Lichtman upgrades Insulet (NASDAQ:PODD) from Perform to Outperform and lowers the price target from $300 to $275.
52 Biggest Movers From Friday
Gainers
Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share.
Mid-Day Market Update: US Stocks Turn Positive; Nasdaq Surges 2%
US stocks turned higher, with all the three major indices recording gains. The Nasdaq climbed more than 2% following stronger-than-expected earnings results from Apple Inc. (NASDAQ: AAPL).
33 Stocks Moving In Friday’s Mid-Day Session
Gainers
Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 126% to $2.6219. Imperial Petroleum, last month, posted Q3 revenue of $4.1 million.
Insulet Announced FDA Clearance of its Omnipod® 5 Automated Insulin Delivery System, First Tubeless System with Smartphone Control
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received clearance from the U.S.